Be Biopharma unveils promising preclinical results for hypophosphatasia treatment using engineered B cell medicines
Be Biopharma, Inc. has presented groundbreaking preclinical findings that underscore the potential of Engineered B Cell Medicines (BCMs) as a novel therapeutic avenue for Hypophosphatasia ... Read More
Profluent rakes in $44M in funding to revolutionize protein design with AI
Profluent, a pioneering AI-first protein design company, has successfully closed an additional $35M in financing, bringing the total capital raised to an impressive $44M. This ... Read More